Aug 2026· Neuropharmacology· Vol 300, pp.
111129
· 0 citations· 75 references
Medicine
TL;DR
Results indicate that hippocampal GPR55 may improve cognitive dysfunction by regulating the AKT/GSK3β and ERK signaling pathways, highlighting its crucial role in AD.
Abstract
Background
Alzheimer's disease (AD) is characterized by progressive memory loss and cognitive decline. G protein-coupled receptor 55 (GPR55) has been linked to cognitive regulation, yet its precise role in AD pathogenesis remains unclear.
Objectives
Here, we investigated the role of GPR55 in AD and its molecular mechanism.
Methods
This study utilized APP/PS1 and GPR55 knockout (GPR55KO) mice to investigate the role and possible mechanism of GPR55 in AD.
Results
We observed progressive reduction of GPR55 levels in the hippocampus of aging APP/PS1 mice. Conversely, hippocampal GPR55 overexpression rescued cognitive deficits, neuroinflammation, and impairment of synaptic plasticity in APP/PS1 mice. Moreover, GPR55 activation reduced neuronal death and memory impairments in APP/PS1 mice. In addition, aged GPR55KO mice showed cognitive deficits, but hippocampal GPR55 reexpression improved cognition. We also demonstrated that GPR55 activation mitigates Aβ1-42-induced synaptic damage and apoptosis in HT22 cells. Further studies revealed that in both animal and cell models, the activation levels of P-AKT/AKT and P-GSK3β/GSK3β were significantly decreased, and the activation level of P-ERK/ERK was markedly increased, while upregulation of GPR55 reversed this trend.
Conclusions
These results indicate that hippocampal GPR55 may improve cognitive dysfunction by regulating the AKT/GSK3β and ERK signaling pathways, highlighting its crucial role in AD.
Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) deposition, yet the mechanisms underlying Aβ-induced neuronal damage remain elusive. Emerging evidence implicates ferroptosis, an iron-dependent form of regulated cell death, in AD pathology. We hypothesized that dysfunction of the Nrf2 pathway critically l...
Neuropsychiatric symptoms can emerge early in Alzheimer's disease (AD), but whether innate fear is altered prior to amyloid plaque deposition remains unclear. This study aimed to examine innate fear responses in young adult male APP/PS1 mice and to evaluate whether D-cycloserine (DCS) rescues such deficits via GluN2B-c...
Bin Zhang, Zhe-Ye Wang, Xin-Jie Zhao et al.· Pharmacology, Biochemistry a...· 0 citations
It is shown that a disease-associated microglial subtype, characterized by elevated GPNMB expression and enriched for polygenic AD risk, expands with AD pathology and shows increased phagocytic activity, and MITF is identified as an upstream regulator required to maintain this microglial state.
Donghoon Lee, James M. Vicari, Christian Porras et al.· Nature Genetics· 1 citation
OBJECTIVE
Alzheimer's disease is a progressive neurological disorder characterized by synaptic injury and loss in its early stage. This study aimed to investigate the effects of treadmill exercise on Alzheimer's disease mice, focusing on the related molecular mechanism of axonal transport.
METHOD
In this study, 3-mon...
Bai-Xia Li, Zhi-Lin Zhang, He-Gui Bao et al.· NeuroReport· 0 citations
These findings identify β- arrestin2 as a sex-dependent node linking Aβ pathology to cognitive outcomes in males but not females, underscoring the necessity of sex-stratified consideration in the design of GPCR-targeted Alzheimer’s disease therapeutics.
Fatemeh A. Panahi, Fatemeh Babaei, Tash-Lynn L. Colson et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.